Agomab Says Phase 1 Data In 10 IPF Patients Show Favorable Safety, Target Engagement For Inhaled AGMB-447; Submits CTA For 120-Patient Phase 2 INSPIRIA Study, Targets Start In H2 2026
Share
Why It Matters
Agomab tested a new lung medicine on 10 people and it seemed safe. The company is moving forward to test it on more people next year.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.